Sarclisa® (isatuximab-irfc)
for Multiple Myeloma

Sarclisa (isatuximab-irfc) is a targeted therapy used to treat multiple myeloma. It is combined with pomalidomide and dexamethasone after at least two prior treatments, with carfilzomib and dexamethasone after 1–3 prior therapies, or with bortezomib, lenalidomide, and dexamethasone in newly diagnosed patients not eligible for stem cell transplant. Sarclisa binds to CD38 on myeloma cells, promoting cell death and immune response activation.

Heart
Medication Guide Icon Medication Guide
Patient Website Icon Patient Website
Efficacy Data Icon Efficacy Data
New Articles Icon New Articles
Savings and Support Icon Savings and Support
Company MD Payments Icon Company MD Payments
Clinical Trials Icon Clinical Trials
Adverse Event Report Icon Adverse Event Report
Other top medicines used to treat Multiple Myeloma